Antibiotics and Clostridium difficile

Microbes and Infection

Volumn 1, Issue 5, 1999, Pages 377-384

  Freeman, Jane ^a   Wilcox, Mark H ^a  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

Adhesion; Antibiotic associated colitis; Clostridium difficile infection; Pseudomembranous colitis; Toxin production

Indexed keywords

AMOXICILLIN; AMPICILLIN; ANTIBIOTIC AGENT; CEFAMANDOLE; CEFAZOLIN; CEFOPERAZONE; CEFOTAXIME; CEFOTETAN; CEFOXITIN; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ERYTHROMYCIN; FLUOROURACIL; METHOTREXATE; MEZLOCILLIN; MICONAZOLE; PENICILLIN DERIVATIVE; PRISTINAMYCIN; SULFALAZINE; TETRACYCLINE;

ANTIBIOTIC THERAPY; BACTERIAL COLONIZATION; BACTERIAL VIRULENCE; BACTERIUM ADHERENCE; CLOSTRIDIUM DIFFICILE; DIARRHEA; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PSEUDOMEMBRANOUS COLITIS; REVIEW; TOXIN SYNTHESIS;

BACTERIA (MICROORGANISMS); CLOSTRIDIUM DIFFICILE; POSIBACTERIA;

EID: 0032726458     PISSN: 12864579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1286-4579(99)80054-9     Document Type: Review

References (71)

1. Bartlett J.G., Onderdonk A.B., Cisneros R.L., Kasper D.L. Clindamycin-associated colitis due to toxin-producing species of Clostridium in hamsters. J. Infect. Dis. 136:1977;701-705.
2. George R.H., Symonds J.M., Dimock F., Brown J.D., Arabi Y., Shinagawa N., Keighley M.R.B., Alexander-William J., Burdon D.W. Identification of Clostridium difficile as a cause of pseudomembranous colitis. Br. Med. J. 1:1978;695.
3. Bartlett J.G. Management of Clostridium difficile infection and other antibiotic-associated diarrhoeas. Eur. J. Gastroenterol. Hepatol. 3:1996;11054-11061.
4. Anand A., Glatt A.E. Clostridium difficile infection associated with antineoplastic chemotherapy: A review. Clin. Infect. Dis. 17:1993;109.
5. Jones E.M., Kirkpatrick B.L., Feeney R., Reeves D.S., Macgowan A.P. Hospital-acquired Clostridium difficile diarrhoea. Lancet. 349:1997;1176-1177.
6. George W.L. Antimicrobial agent-associated colitis and diarrhoea: historical background and clinical aspects. Rev. Infect. Dis. 6 Suppl. 1 S:1984;208-213.
7. Borriello S.P., Dodson A.P. Clostridium difficile infection of the gut. J. Clin. Pathol. 49:1996;529-532.
8. Spencer R.C. The role of antimicrobial agents in the aetiology of Clostridium difficile-associated disease. J. Antimicrob. Chemother. 41 Suppl. C:1998;21-27.
9. Fekety R. Antibiotic associated colitis. Mandell G.L, Bennett J.E, Dolin R. Mandell Douglas and Bennett's Principles and Practice of Infectious Diseases. 4th edition :1995;978-987 Churchill Livingstone, New York.
10. Simor A.E., Yake S.L., Tsimidis K. Infection due to Clostridium difficile among elderly residents of a long-term-care facility. Clin. Infect. Dis. 17:1993;672-678.
11. Kelly C.P., Pothoulakis C., Lamont J.T. Clostridium difficile colitis. New Engl. J. M. 330:1994;257-262.
12. Bartlett J.G. Antimicrobial agents implicated in Clostridium difficile toxin-associated diarrhoea or colitis. John Hopk. Med. J. 149:1981;6-9.
13. Aronsson B., Möllby R., Nord C.E. Diagnosis and epidemiology of Clostridium difficile enterocolitis in Sweden. J. Antimicrob. Chemother. 14 Suppl. D:1984;85-95.
14. Aronsson B., Möllby R., Nord C.E. Antimicrobial agents and Clostridium difficile in acute enteric disease: epidemiological data from Sweden 1980-1982. J. Infect. Dis. 151:1985;476-481.
15. Ho M., Yang D., Wyle F.E., Mulligan M.E. Increased incidence of Clostridium difficile-associated diarrhoea following decreased restriction of antibiotic use. Clin. Infect. Dis. 23 Suppl. 1:1996;102-106.
16. McNulty C., Logan M., Donal I.P., Ennis D., Taylor D., Baldwin R.N., Bannerjee N., Cartwright K.A.V. Successful control of Clostridium difficile infection in an elderly care unit through use of a restrictive antibiotic policy. J. Antimicrob. Chemother. 40:1997;707-711.
17. Macgowan A.P., Feeney R., Brown I., McCulloch S.Y., Reeves D.S., Lovering A.M. Health care resource utilisation and antimicrobial use in elderly patients with community-acquired lower respiratory tract infection who develop Clostridium difficile-associated diarrhoea. J. Antimicrob. Chemother. 39:1997;537-541.
18. Fekety R., McFarland L.V., Surawicz C.M., Greenberg R.N., Elmer G.W., Mulligan M.E. Recurrent Clostridium difficile diarrhoea: characteristics and risk factors for patients enrolled in a prospective randomised double-blinded trial. Clin. Infect. Dis. 24:1997;324-333.
19. Karlström O., Fryklund B., Tullus K., Burman L.G. the Swedish C. difficile study group., A prospective nationwide study of Clostridium difficile-associated diarrhoea in Sweden. Clin. Infect. Dis. 26:1998;141-145.
20. Hutin Y., Casin I., Lesprit P., Welker Y., Decazes J.M., Lagrange P., Modaï J., Molina J.M. Prevalence of and risk factors for Clostridium difficile colonisation at admission to and infectious diseases ward. Clin. Infect. Dis. 24:1997;920-924.
21. Tedesco F., Barton R.W., Alpers D.H. Clindamycin-associated colitis: a prospective study. Ann. Inter. M. 81:1974;429-433.
22. Larson H.E., Parry J.V., Price A.B., Davies D.R., Dolby J., Tyrell D.A. Undescribed toxin in pseudomembranous colitis. Brit. Med. J. i:1977;1246-1248.
23. Larson H.E., Borriello S.P. Quantitative study of antibiotic-induced susceptibility to Clostridium difficile enterocaecitis in hamsters. Antimicrob. Agents Chemother. 34:1990;1348-1353.
24. Pear S.M., Williamson T.H., Bettin K.M., Gerding D.N., Galgiani J.N. Decrease in nosocomial Clostridium difficile-associated diarrhoea by restricting clindamycin use. Ann. Intern. M. 120:1994;272-277.
25. Willey S., Bartlett J.G. Cultures for Clostridium difficile in stools containing a cytotoxin neutralised by Clostridium sordellii antitoxin. J. Clin. Microbiol. 10:1979;880-884.
26. Quale J., Landmann D., Saurina G., Atwood E., Ditore V., Patel K. Manipulation of a hospital antimicrobial formulary to control an outbreak of vancomycin-resistant enterococci. Clin. Infect. Dis. 23:1996;1020-1025.
27. Silva J., Fekety R., Werk C., Ebright J., Cudmore M., Batts D., Syrjmaki C., Lukens J. Inciting and aetiological agents of colitis. Rev. Infect. Dis. 6Suppl.1:1984;S 214-221.
28. Golledge C.L., McKenzie T., Riley T.V. Extended spectrum cephalosporins and Clostridium difficile. J. Antimicrob. Chemother. 23:1989;929-931.
29. DeLalla F., Privitera G., Ortisi G., Rizzardini G., Santoro D., Pagano A., Rinaldi E., Scarpellini P. Third generation cephalosporins as a risk factor for Clostridium difficile-associated disease: a four-year survey in a general hospital. J. Antimicrob. Chemother. 23:1989;623-631.
30. Cartmill T.D., Panigrahi H., Worsley M.A., McCann D., Nice C.N., Keith E. Management and control of a large outbreak of diarrhoea due to Clostridium difficile. J. Hosp. Infect. 27:1994;1-15.
31. Bodey G.P., Fainstein V., Garcia I., Rosenbaum B., Wong Y. Effect of broad-spectrum cephalosporins on the microbial flora of recipients. J. Infect. Dis. 148:1983;892-897.
32. Impallomeni M., Galletly N.P., Wort S., Starr J.M., Rogers T.R. Increased risk of diarrhoea caused by Clostridium difficile in elderly patients receiving cefotaxime. Brit. Med. J. 311:1995;1345-1346.
33. British Thoracic Society. Guidelines for the management of community acquired pneumonia in adults admitted to hospital. Brit. Med. J. 49:1993;50-346.
34. Anand A., Bashey B., Mir T., Glatt A.E. Epidemiology clinical manifestations and outcome of Clostridium difficile-associated diarrhoea. Am. J. Gastroenterol. 89:1994;519-523.
35. Nord C.E., Brismar B., Kasholm-Tengve B., Tunevall G. Effect of piperacillin-tazobactam treatment on human bowel microflora. J. Antimicrob. Chemother. 31Suppl.A:1993;61-65.
36. Hirschorn L.R., Trnka Y., Onderdonk A., Lee M.L.T., Platt R. Epidemiology of community-acquired Clostridium difficile-associated diarrhoea. J. Infect. Dis. 169:1994;127-133.
37. Mitchell D.K., Van R., Mason E.H., Norris D.M., Pickering L.K. Prospective study of toxigenic Clostridium difficile in children given amoxicillin/clavulanate for otitis media. Paed. Infect. Dis. J. 15:1996;514-519.
38. Schacht J.T., Arcieri G., Branolte J., Chysky V., Grifith E., Gruenwaldt G., Hullmann R., Konopka C.A., O'Brien B. Worldwide clinical data on efficacy and safety of ciprofloxacin. Infection. 16Suppl.1:1988;29-43.
39. Falsen E., Kaijser B., Nehls L., Nygren B., Svedhem A. Clostridium difficile in relation to other enteric bacterial pathogens. J. Clin. Microbiol. 12:1980;297-300.
40. Bates C., Wilcox M.H., Spencer R.C., Harris D.M. Ciprofloxacin and Clostridium difficile infection. Lancet. 336:1990;1193.
41. Hillman D. Ciprofloxacin as a cause of Clostridium difficile-associated diarrhoea in an HIV antibody positive patient. J. Infect. 21:1990;205-207.
42. Low N., Harries A. Ciprofloxacin and pseudomembranous colitis. Lancet. 336:1990;1510.
43. Cain D.B., O'Connor M.E. Pseudomembranous colitis associated with ciprofloxacin. Lancet. 336:1990;946.
44. Golledge C.L., Carson C.F., O'Neill G.L., Bowman R.A., Riley T.V. Ciprofloxacin and Clostridium difficile-associated diarrhoea. J. Antimicrob. Chemother. 30:1992;141-147.
45. Smith J.T., Lewin C.S. Chemistry and mechanisms of action of quinolone antibacterials. Riole V.T. The Quinolones. 1988;28-82 Academic Press, London.
46. Braegger C.P., Nadal D. Clarithromycin and pseudomembranous enterocolitis. Lancet. 343:1994;2-241.
47. Talon D., Bailly P., Delmée M., Thouverez M., Mulin B., Iehl-Robert M., Cailleux V., Michel-Briand Y. Use of pulsed-field gel electrophoresis for investigation of an outbreak of Clostridium difficile among geriatric patients. Eur. J. Clin. Microbiol. Infect. Dis. 14:1995;987-993.
48. DeCourcy J., Mackinnon J. Pseudomembranous colitis and trimethoprim. Brit. Med. J. 290:1985;1112.
49. Gordin F., Gibert C., Schmidt M.E. Clostridium difficile colitis associated with trimethoprim-sulfamethoxazole given as prophylaxis for Pneumoncystis carinii pneumonia. Am. J. M. 96:1994;5-94.
50. Golledge C.L., Riley T.V. Clostridium difficile-associated diarrhoea after doxycycline malaria prophylaxis. Lancet. 345:1995;1377-1378.
51. Riley T.V., Wetheral F., Bowman J., Mogyorosy J., Golledge C.L. Diarrhoeal disease due to Clostridium difficile in general practice. Pathology. 23:1991;346-349.
52. Ambrose N.S., Johnson M., Burdon D.W., Keighley M.R.B. The influence of single dose intravenous antibiotics on faecal flora and emergence of Clostridium difficile. J. Antimicrob. Chemother. 15:1985;319-326.
53. Privetera G., Scarpellini P., Ortisi G., Nicastro G., Nicolini R., DeLalla F. Prospective study of Clostridium difficile intestinal colonisation and disease following single dose antibiotic prophylaxis in surgery. Antimicrob. Agents Chemother. 35:1991;208-210.
54. Kreisel D., Savel T.C., Silver A.L., Cunningham J.D. Surgical antibiotic prophylaxis and Clostridium difficile toxin positivity. Arch. Surg. 130:1995;989-993.
55. Borriello S.P., Barclay F.E. An in-vitro model of colonisation resistance to Clostridium difficile infection. J. Med. Microbiol. 21:1986;299-309.
56. Larson H.E., Welch A. In-vitro and in-vivo characterisation of resistance to colonisation resistance with Clostridium difficile. J. Med. Microbiol. 38:1993;103-108.
57. Borriello S.P. The influence of the normal flora on Clostridium difficile colonisation of the gut. Ann. M. 22:1990;61-67.
58. Rolfe R.D., Helebian S., Finegold S.M. Bacterial interference between Clostridium difficile and normal faecal flora. J. Infect. Dis. 143:1981;470-475.
59. Eley A., Greenwood D. In-vitro activity of ceftizoxime against Bacteroides fragilis: comparison with benzyl penicillin cephalothin and cefoxitin. Antimicrob. Agents Chemother. 20:1981;332-335.
60. Canawati H.N. A reassessment of the activity of the third-generation cephalosporins against anaerobes and Staphylococcus aureus. Am. J. Surgery. 164Suppl.4A:1992;24-27.
61. Starr J.M., Rogers T.M., Impallomeni M. Hospital-acquired Clostridium difficile diarrhoea and herd immunity. Lancet. 349:1997;426-428.
62. Johnson S., Gerding D.N. Clostridium difficile-associated diarrhoea. Clin. Infect. Dis. 26:1998;1027-1036.
63. Borriello S.P., Barclay F.E. Protection of hamsters against Clostridium difficile ileocaecitis by prior colonisatioin with non-pathogenic strains. J. Med. Microbiol. 19:1985;339-350.
64. Seal D., Borriello S.P., Barclay F., Welch A., Piper M., Bonnycastle M. Treatment of relapsing Clostridium difficile diarrhoea by administration of a non-toxigenic strain. Eur. J. Clin. Microbiol. 6:1987;51-53.
65. Honda T., Hernadez I., Katohi T., Miwatani T. Stimulation of enterotoxin production of Clostridium difficile by antibiotics. Lancet. I:1983;655.
66. Borriello S.P., Welch A.R., Barclay F.E., Davies H.A. Mucosal association by Clostridium difficile in the hamster gastrointestinal tract. J. Med. Microbiol. 25:1988;191-196.
67. Naaber P., Lehto E., Salminen S., Mikelsaar M. Inhibition of adhesion of Clostridium difficile to Caco-2 cells. FEMS Immunol. Med. Microbiol. 14:1996;205-209.
68. Schifferli D.M., Beachey E.H. Bacterial adhesion: modulation by antibiotics which perturb protein synthesis. Antimicrob. Agents Chemother. 32:1988;1603-1608.
69. Krishna M.M., Powell N.B.L., Borriello S.P. Cell surface properties of Clostridium difficile: haemagglutination relative hydrophobicity and charge. J. Med. Microbiol. 44:1996;115-123.
70. Eveillard M., Fourel V., Barc M.C., Kerneis S., Coconnier M.H., Karjalainen T. Identification and characterisation of adhesive factors of Clostridium difficile involved in adhesion to human colonic enterocyte-like-Caco-2 and mucus secreting HT29 cells in culture. Mol. Microbiol. 7:1993;371-381.
71. Karjalainen T., Barc M.C., Collignon A., Troll S., Boureau H., Cotte-Lafitte J., Bourlioux P. Cloning of a genetic determinant from Clostridium difficile involved in adherence to tissue culture cells and mucus. Infect. Immun. 62:1994;4347-4355.